Search for: "In re Sanofi Securities Litigation"
Results 1 - 20
of 42
Sort by Relevance
|
Sort by Date
23 Jan 2024, 9:01 pm
The $5.8 billion[2] specifically secured in securities-related class actions in the U.S. was also up 18% from 2022. [read post]
22 Dec 2022, 7:59 am
Sanofi, No. 21-757, with merits briefs due beginning December 27, 2022. [read post]
19 Jul 2022, 2:59 pm
As with our original study, and contrary to conventional wisdom, this analysis indicates that federal securities claims brought against biotech companies regarding the regulatory approval process actually are dismissed far more frequently than average at an early stage in the litigation.[5] III. [read post]
30 Mar 2022, 12:13 pm
In Re Turkey Antitrust Litigation at 12. [read post]
24 Feb 2022, 6:12 pm
Google LLC; Universal Secure Registry LLC v. [read post]
16 Jul 2021, 11:59 am
The dietary supplement and personal care product space continued to see enforcement on false CBD, COVID, and fertility claims as well as related litigation involving “germ-killing” claims on hand sanitizers and wipes. [read post]
19 Apr 2021, 10:56 am
Who May Have a Claim in the Zantac Mass Tort Litigation? [read post]
15 Apr 2021, 10:51 am
Sanofi-Aventis U.S. [read post]
1 Apr 2016, 1:25 pm
In In re Sanofi Securities Litigation, No. 15-588-cv, 2016 U.S. [read post]
6 Jan 2015, 4:14 am
Supreme Court as we awaited the outcome of the Halliburton case, which potentially could have been a game changer in the world of securities class action litigation. [read post]
18 Nov 2014, 11:16 am
None of them very long (at least by DDLaw Blog standards), but we think that each will be of interest to at least some our readers.On Generic Plaintiffs’ Preemption “Win” in New JerseyThis piece is from the non-Dechert side of the blog.Plaintiffs alleging failure to warn of the risks of a generic drug scored a “win” of sorts in In re Reglan Litigation, 2014 WL 5840281 (N.J. [read post]
29 Aug 2012, 4:05 pm
Litigation will continue against the other 4. [read post]
6 Jan 2012, 3:00 am
Apotex argued that Sanofi should not be able to come to Canada to get an award in respect of the same Apo-clopidogrel in respect of which they had already secured judgment and payment in the US. [read post]
30 Nov 2009, 12:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: David Lammy announces research programme to explore role of IP as facilitator of innovation and economic growth (IPKat) (IPKat) (IAM) USPTO to use Indian traditional knowledge database (Managing Intellectual Property) (Spicy IP) (Securing Innovation) Global Global - General Forbidden City, global firm and thank you… [read post]
29 Sep 2009, 5:05 am
” In re Sanofi-Aventis Sec. [read post]
9 Apr 2009, 9:27 am
(PatLit) UNCITRAL – IP security and an absurdly tight deadline for response (IP finance) Horse race sponsorship: what is central to centralised deals? [read post]
16 Jan 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: CAFC: In re Comiskey rehearing en banc falls two votes short; important dissent by Moore J (Hal Wegner) (Inventive Step) (Patently-O) (Washington State Patent Law Blog) (Peter Zura's 271 Patent Blog) (Law360) (Patent Prospector) District Court Delaware: Document shredding voids 12 Rambus patents: Rambus v Micron Technology… [read post]
20 Dec 2008, 3:00 am
gain upper hand in Blu-ray DRM battle (Ars Technica) Africa South African Times report on state of African music, lack of support and protection (Afro-IP) Australia Australian Copyright Tribunal: consumer valuation of copyright: Audio-Visual Copyright Society (t/a Screenrights) v Foxtel and Re PPCA (IPKat) (IP finance) Innovation patents in Australia. [read post]
15 Dec 2008, 2:00 pm
If we were the Psychology Daily we might suggest something about salving a guilty conscience, but we're the Litigation Daily. [read post]
5 Sep 2008, 11:01 pm
: (Excess Copyright), (Michael Geist), Opinion and analysis of C-61: (Michael Geist), (Michael Geist), (Michael Geist), (Michael Geist), (Michael Geist), (Michael Geist), 61 reforms to C-61: (Day 50: Education harms – lessons contain limited definition of students – Michael Geist), (Day 51: Education internet exception is unnecessary – Michael Geist), (Day 52: Education internet exception is harmful – Michael Geist), (Day 53: Education internet exception… [read post]
